News & Updates

Modulation of gut microbiome using the SIM01 synbiotic formula significantly improves neuropsychiatric and gastrointestinal (GI) symptoms of long COVID, according to results of the randomized, triple-blind, placebo-controlled RECOVERY study conducted by researchers from the Chinese University of Hong Kong (CUHK).

Both the 2-dose and 3-dose vaccination schedules of the four-component meningococcal serogroup B vaccine (4CMenB) appear to provide protection against a panel epidemiologically relevant strains in adolescents and young adults, according to a phase III study presented at ESPID 2023.

In the ENSEMBLE PLUS study, there appears to be no difference in terms of the frequency and severity of infusion-related reactions (IRRs) between the conventional and shorter infusions of ocrelizumab for the treatment of early relapsing-remitting multiple sclerosis (RRMS). However, patients gravitated towards the shorter regimen more than the conventional method.

Undergoing epilepsy surgery appears to yield clinically meaningful gains in quality of life (QoL), according to the results of a meta-analysis.

The use of rivaroxaban in nonhospitalized patients with symptomatic COVID-19 falls short of reducing the composite endpoint of venous and arterial thrombotic events, hospitalization, and death, according to data from PREVENT-HD*.